Pfizer launches early study of cancer drug atirmociclib in healthy volunteers

NCT ID NCT07215078

Recruiting now Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study by Pfizer will give atirmociclib to 72 healthy adults to see how the drug moves through the body at different doses after a meal. Participants will receive four single doses in a random order, with blood samples taken to measure drug levels. The goal is to find the right dose for future studies, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: atirmociclib (PF-07220060)
What this could lead to: If successful, this study will help determine the right dose of atirmociclib for future trials, potentially leading to a treatment for certain cancers.
What could go wrong: This is a very early Phase 1 study in healthy volunteers, not patients. It only measures drug levels and short-term safety; it cannot show whether the drug works against any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Pfizer Clinical Research Unit - New Haven
RECRUITING

New Haven, Connecticut, 06511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.